Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation

Hideyuki Yoshida, Akihiro Kimura, Tomohiro Fukaya, Takashi Sekiya, Rimpei Morita, Takashi Shichita, Hiromasa Inoue, Akihiko Yoshimura

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Th17 cells, which have been implicated in autoimmune diseases, require STAT3 signaling activated by IL-6 or IL-23 for their development. Other Th1 and Th2 cytokines such as IL-2, IFN-γ and IL-4 strongly suppress Th17 development. Recently, CP-690,550 (tofacitinib), originally developed as a JAK3 inhibitor, has been shown to be effective in phase III clinical trials of rheumatoid arthritis and collagen-induced arthritis (CIA) models, but the precise mechanism of the effect, especially with respect to Th17 cells, is poorly understood. To our surprise, a low dose CP-690,550 was found to accelerate the onset of experimental autoimmune encephalomyelitis (EAE) at a concentration that suppressed CIA. At an early stage after immunization, more IL-17 production was observed in 15. mg/kg body weight CP-690,550-treated mice than in untreated mice. In vitro, CP-690,550 inhibited both Th1 and Th2 development, while promoting Th17 differentiation at 10-50. nM concentrations. Enhancement of Th17 by CP-690,550 is probably due to suppression of IL-2 signaling, because anti-IL-2 antibodies cancel the Th17-promoting effect of CP-690,550. CP-690,550 selectively inhibited IFN--induced STAT1, IL-4-induced STAT6 and IL-2-induced STAT5 at 3-30. nM, while suppression of IL-6-induced STAT3 phosphorylation required a concentration greater than 100. nM. In HEK293T cells, CP-690,550 less effectively suppressed JAK1-mediated STAT3 phosphorylation compared with JAK3. These results suggest that CP-690,550 has a different effects among JAKs and STATs, thereby affecting helper T cell differentiation, and murine autoimmune disease models.

Original languageEnglish
Pages (from-to)234-240
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume418
Issue number2
DOIs
Publication statusPublished - 2012 Feb 10

Fingerprint

Autoimmune Experimental Encephalomyelitis
Interleukin-2
Th17 Cells
Phosphorylation
Experimental Arthritis
Interleukin-4
Autoimmune Diseases
Interleukin-6
Collagen
tofacitinib
Immunization
Interleukin-23
Phase III Clinical Trials
T-cells
Interleukin-17
Helper-Inducer T-Lymphocytes
Cell Differentiation
Rheumatoid Arthritis
Body Weight
Cytokines

Keywords

  • Cytokine signaling
  • EAE
  • Helper T cells
  • Mouse

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. / Yoshida, Hideyuki; Kimura, Akihiro; Fukaya, Tomohiro; Sekiya, Takashi; Morita, Rimpei; Shichita, Takashi; Inoue, Hiromasa; Yoshimura, Akihiko.

In: Biochemical and Biophysical Research Communications, Vol. 418, No. 2, 10.02.2012, p. 234-240.

Research output: Contribution to journalArticle

Yoshida, Hideyuki ; Kimura, Akihiro ; Fukaya, Tomohiro ; Sekiya, Takashi ; Morita, Rimpei ; Shichita, Takashi ; Inoue, Hiromasa ; Yoshimura, Akihiko. / Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. In: Biochemical and Biophysical Research Communications. 2012 ; Vol. 418, No. 2. pp. 234-240.
@article{79d3ae0221bc40ba9688b5a3193c9c57,
title = "Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation",
abstract = "Th17 cells, which have been implicated in autoimmune diseases, require STAT3 signaling activated by IL-6 or IL-23 for their development. Other Th1 and Th2 cytokines such as IL-2, IFN-γ and IL-4 strongly suppress Th17 development. Recently, CP-690,550 (tofacitinib), originally developed as a JAK3 inhibitor, has been shown to be effective in phase III clinical trials of rheumatoid arthritis and collagen-induced arthritis (CIA) models, but the precise mechanism of the effect, especially with respect to Th17 cells, is poorly understood. To our surprise, a low dose CP-690,550 was found to accelerate the onset of experimental autoimmune encephalomyelitis (EAE) at a concentration that suppressed CIA. At an early stage after immunization, more IL-17 production was observed in 15. mg/kg body weight CP-690,550-treated mice than in untreated mice. In vitro, CP-690,550 inhibited both Th1 and Th2 development, while promoting Th17 differentiation at 10-50. nM concentrations. Enhancement of Th17 by CP-690,550 is probably due to suppression of IL-2 signaling, because anti-IL-2 antibodies cancel the Th17-promoting effect of CP-690,550. CP-690,550 selectively inhibited IFN--induced STAT1, IL-4-induced STAT6 and IL-2-induced STAT5 at 3-30. nM, while suppression of IL-6-induced STAT3 phosphorylation required a concentration greater than 100. nM. In HEK293T cells, CP-690,550 less effectively suppressed JAK1-mediated STAT3 phosphorylation compared with JAK3. These results suggest that CP-690,550 has a different effects among JAKs and STATs, thereby affecting helper T cell differentiation, and murine autoimmune disease models.",
keywords = "Cytokine signaling, EAE, Helper T cells, Mouse",
author = "Hideyuki Yoshida and Akihiro Kimura and Tomohiro Fukaya and Takashi Sekiya and Rimpei Morita and Takashi Shichita and Hiromasa Inoue and Akihiko Yoshimura",
year = "2012",
month = "2",
day = "10",
doi = "10.1016/j.bbrc.2011.12.156",
language = "English",
volume = "418",
pages = "234--240",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation

AU - Yoshida, Hideyuki

AU - Kimura, Akihiro

AU - Fukaya, Tomohiro

AU - Sekiya, Takashi

AU - Morita, Rimpei

AU - Shichita, Takashi

AU - Inoue, Hiromasa

AU - Yoshimura, Akihiko

PY - 2012/2/10

Y1 - 2012/2/10

N2 - Th17 cells, which have been implicated in autoimmune diseases, require STAT3 signaling activated by IL-6 or IL-23 for their development. Other Th1 and Th2 cytokines such as IL-2, IFN-γ and IL-4 strongly suppress Th17 development. Recently, CP-690,550 (tofacitinib), originally developed as a JAK3 inhibitor, has been shown to be effective in phase III clinical trials of rheumatoid arthritis and collagen-induced arthritis (CIA) models, but the precise mechanism of the effect, especially with respect to Th17 cells, is poorly understood. To our surprise, a low dose CP-690,550 was found to accelerate the onset of experimental autoimmune encephalomyelitis (EAE) at a concentration that suppressed CIA. At an early stage after immunization, more IL-17 production was observed in 15. mg/kg body weight CP-690,550-treated mice than in untreated mice. In vitro, CP-690,550 inhibited both Th1 and Th2 development, while promoting Th17 differentiation at 10-50. nM concentrations. Enhancement of Th17 by CP-690,550 is probably due to suppression of IL-2 signaling, because anti-IL-2 antibodies cancel the Th17-promoting effect of CP-690,550. CP-690,550 selectively inhibited IFN--induced STAT1, IL-4-induced STAT6 and IL-2-induced STAT5 at 3-30. nM, while suppression of IL-6-induced STAT3 phosphorylation required a concentration greater than 100. nM. In HEK293T cells, CP-690,550 less effectively suppressed JAK1-mediated STAT3 phosphorylation compared with JAK3. These results suggest that CP-690,550 has a different effects among JAKs and STATs, thereby affecting helper T cell differentiation, and murine autoimmune disease models.

AB - Th17 cells, which have been implicated in autoimmune diseases, require STAT3 signaling activated by IL-6 or IL-23 for their development. Other Th1 and Th2 cytokines such as IL-2, IFN-γ and IL-4 strongly suppress Th17 development. Recently, CP-690,550 (tofacitinib), originally developed as a JAK3 inhibitor, has been shown to be effective in phase III clinical trials of rheumatoid arthritis and collagen-induced arthritis (CIA) models, but the precise mechanism of the effect, especially with respect to Th17 cells, is poorly understood. To our surprise, a low dose CP-690,550 was found to accelerate the onset of experimental autoimmune encephalomyelitis (EAE) at a concentration that suppressed CIA. At an early stage after immunization, more IL-17 production was observed in 15. mg/kg body weight CP-690,550-treated mice than in untreated mice. In vitro, CP-690,550 inhibited both Th1 and Th2 development, while promoting Th17 differentiation at 10-50. nM concentrations. Enhancement of Th17 by CP-690,550 is probably due to suppression of IL-2 signaling, because anti-IL-2 antibodies cancel the Th17-promoting effect of CP-690,550. CP-690,550 selectively inhibited IFN--induced STAT1, IL-4-induced STAT6 and IL-2-induced STAT5 at 3-30. nM, while suppression of IL-6-induced STAT3 phosphorylation required a concentration greater than 100. nM. In HEK293T cells, CP-690,550 less effectively suppressed JAK1-mediated STAT3 phosphorylation compared with JAK3. These results suggest that CP-690,550 has a different effects among JAKs and STATs, thereby affecting helper T cell differentiation, and murine autoimmune disease models.

KW - Cytokine signaling

KW - EAE

KW - Helper T cells

KW - Mouse

UR - http://www.scopus.com/inward/record.url?scp=84856628204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856628204&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2011.12.156

DO - 10.1016/j.bbrc.2011.12.156

M3 - Article

C2 - 22252297

AN - SCOPUS:84856628204

VL - 418

SP - 234

EP - 240

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -